Literature DB >> 6272957

Epstein-Barr virus antibodies in patients with ataxia-telangiectasia and other immunodeficiency diseases.

J H Joncas, A Wills, E Reece, Z Fox.   

Abstract

An unusual antibody response to the Epstein-Barr virus (EBV) has been noted in patients with ataxia-telangiectasia. Of a group of 16 such patients 8 were found to have antibodies in their serum to the EBV viral capsid antigen (VCA), and 4 of them also had antibodies to the EBV early antigen (EA); antibodies to the nuclear antigen (EBNA), however, were absent in 3 of the 8. The antibody pattern persisted for more than 2 years in the patients available for follow-up study. In comparison, of 24 patients with various other immunodeficiency syndromes 9 were found to have EBV-VCA antibodies in their serum, but none of the 9 had EA antibodies and 3 lacked EBNA antibodies. Two other groups of subjects, all of whom had EBV-VCA and EBNA antibodies in their serum late after an EBV infection, were also studied; 82 had infectious mononucleosis and 55 were healthy and had no such history. EA antibodies were detected in 45 of the first group during the acute phase of the illness but persisted in only 6 of the 68 who were followed up for more than 2 years, and they were detected in only 7 of the second group.All eight lymphoblastoid cell lines established from the peripheral blood of the four patients with ataxia-telangiectasia who are still available for follow-up study express EBV-VCA, whereas most similar cell lines established from normal individuals express only EBNA. In two of these patients cell-mediated immunity, as assessed from lymphocyte transformation induced by mitogens, was markedly decreased but autologous cell-mediated immune regression of EBV-induced transformation of B (bone-marrow-derived)-lymphocytes was normal. The percentage of T (thymus-derived)-helper cells was greatly decreased in two of the three patients in whom it was measured, and the percentage of T-suppressor cells was greatly increased in one of them, but the percentage of total T-lymphocytes was within normal limits in all three.The possible significance of these findings - in particular, the persistence of EA antibodies and the diminished restriction of expression of EA - in the late development of tumours after an EBV infection in patients with ataxia-telangiectasia deserves careful attention. Finally, the apparent correlation between immunoglobulin deficiency and poor or absent EBNA antibody response warrants further study.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6272957      PMCID: PMC1862718     

Source DB:  PubMed          Journal:  Can Med Assoc J        ISSN: 0008-4409            Impact factor:   8.262


  18 in total

1.  Defective excision repair of gamma-ray-damaged DNA in human (ataxia telangiectasia) fibroblasts.

Authors:  M C Paterson; B P Smith; P H Lohman; A K Anderson; L Fishman
Journal:  Nature       Date:  1976-04-01       Impact factor: 49.962

2.  Epstein-Barr virus (EBV) expression in transformed human lymphoblastoid cell lines from different sources.

Authors:  J Menezes; J H Joncas; P Patel; W Leibold
Journal:  Bibl Haematol       Date:  1975-10

3.  Epstein-Barr virus-related antibody patterns in ataxia-telangiectasia.

Authors:  A I Berkel; W Henle; G Henle; G Klein; F Ersoy; O Sanal
Journal:  Clin Exp Immunol       Date:  1979-02       Impact factor: 4.330

4.  False negative and prozone reactions in tests for antibodies to Epstein-Barr virus-associated nuclear antigen.

Authors:  W Henle; A Guerra; G Henle
Journal:  Int J Cancer       Date:  1974-06-15       Impact factor: 7.396

5.  Limitations of immunofluorescence tests in the diagnosis of infectious mononucleosis.

Authors:  J H Joncas; J C Gilker; A Chagnon
Journal:  Can Med Assoc J       Date:  1974-04-06       Impact factor: 8.262

6.  Antibodies to Epstein-Barr virus-related antigens in nasopharyngeal carcinoma. Comparison of active cases with long-term survivors.

Authors:  W Henle; H C Ho; G Henle; H C Kwan
Journal:  J Natl Cancer Inst       Date:  1973-08       Impact factor: 13.506

7.  Patterns of antibodies to Epstein-Barr virus-induced early antigens in Burkitt's lymphoma. Comparison of dying patients with long-term survivors.

Authors:  W Henle; G Henle; P Gunvén; G Klein; P Clifford; S Singh
Journal:  J Natl Cancer Inst       Date:  1973-05       Impact factor: 13.506

8.  Unusual prevalence of antibodies to Epstein-Barr virus early antigen in ataxia telangiectasia.

Authors:  J Joncas; N Lapointe; F Gervais; M Leyritz; A Wills
Journal:  Lancet       Date:  1977-05-28       Impact factor: 79.321

9.  Abnormalities of immunoregulatory T cells in disorders of immune function.

Authors:  E L Reinherz; A Rubinstein; R S Geha; A J Strelkauskas; F S Rosen; S F Schlossman
Journal:  N Engl J Med       Date:  1979-11-08       Impact factor: 91.245

10.  Nasopharyngeal carcinoma and Burkitt's lymphoma in a Canadian family. I. HLA typing, EBV antibodies and serum immunoglobulins.

Authors:  J H Joncas; E Rioux; J P Wastiaux; M Leyritz; L Robillard; J Menezes
Journal:  Can Med Assoc J       Date:  1976-11-06       Impact factor: 8.262

View more
  4 in total

1.  Ataxia telangiectasia mutated kinase controls chronic gammaherpesvirus infection.

Authors:  Joseph M Kulinski; Steven M Leonardo; Bryan C Mounce; Laurent Malherbe; Stephen B Gauld; Vera L Tarakanova
Journal:  J Virol       Date:  2012-09-19       Impact factor: 5.103

Review 2.  Epstein-Barr virus (EBV)-specific cell-mediated and humoral immune responses in ataxia-telangectasia patients.

Authors:  G Masucci; I Berkel; M G Masucci; I Ernberg; R Szigeti; F Ersoy; O Sanal; O Yegin; G Henle; W Henle
Journal:  J Clin Immunol       Date:  1984-09       Impact factor: 8.317

3.  A familial syndrome of susceptibility to chronic active Epstein-Barr virus infection.

Authors:  J H Joncas; F Ghibu; M Blagdon; S Montplaisir; I Stefanescu; J Menezes
Journal:  Can Med Assoc J       Date:  1984-02-01       Impact factor: 8.262

4.  The natural history of ataxia-telangiectasia (A-T): A systematic review.

Authors:  Emily Petley; Alexander Yule; Shaun Alexander; Shalini Ojha; William P Whitehouse
Journal:  PLoS One       Date:  2022-03-15       Impact factor: 3.752

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.